Tag: Longevity

Investor interest in Longevity Health Holdings, Inc. (NASDAQ: XAGE) spiked during the pre-market session, and at the last check, shares had risen 74.67% to $4.62.

The surge comes after True Health Inc., a major participant in the plasma collection sector and the operator of THPlasma, announced a definitive merger agreement. Due to the merger’s all-stock structure, the merged company will continue to trade on the Nasdaq with the symbol “XAGE.”

Entering the Plasma Therapeutics Market Strategically

Longevity Health had already acquired Carmell Therapeutics in July 2023 and Elevai Skincare in January 2025; this strategic move is the company’s most recent expansion step. XAGE’s growing emphasis on biologics is shown in Elevai’s use of hUM stem cell exosomes, whereas Carmell’s platform is focused on plasma-derived growth factors. Concurrent with the THPlasma agreement, Longevity also announced the mutual termination of its previous deal with 20/20 BioLabs.

THPlasma’s Growth Trajectory and Financial Strength

Although the United States accounts for more than 60% of the world’s plasma supply, there is still a significant need for plasma-derived medicines, which THPlasma is working to answer. From two plasma collection facilities in New Jersey in FY24 to five facilities in New Jersey and Pennsylvania in FY25, the firm is growing quickly.

With guaranteed annual sales offtake agreements totaling $100 million and having achieved cash profitability in FY2024, THPlasma stands out as a fast-growing and financially sound business. The transaction values THPlasma at $59 million with an additional $20 million earnout contingent on achieving financial targets—equating to a 2.5x FY26E revenue multiple.

Longevity Health’s stock is being valued at $3.00 per share in the transaction, reflecting a 12% premium over its July 11 closing price. Notably, the deal includes no cash conditions precedent to closing.

Leadership Structure and Forward-Looking Outlook

Following closing, George Chi, the founder and CEO of THPlasma, will serve as Co-Chairman and CEO, while Rajiv Shukla will take over as Executive Chairman. The deal, which has been unanimously authorized by the boards of both businesses, is anticipated to close in Q4 2025, subject to regulatory and shareholder clearance.

Through improved market access and future M&A possibilities, the combination is expected to propel THPlasma’s expansion, providing Longevity (XAGE) shareholders with value and establishing the merged business as a leading pioneer in the biologics industry.

During today’s pre-market session, Longevity Health Holdings, Inc. (NASDAQ: XAGE) shares jumped 35.95% to $4.16. This notable gain in stock value followed a key regulatory event related to the company’s proposed merger with 20/20 BioLabs, Inc. With a positive ruling from the Nasdaq Hearings Panel, XAGE is permitted to continue listing on The Nasdaq Stock Market, provided that the combined company satisfies the original listing requirements by September 2, 2025.

Strategic Roadmap Endorsement

Following a careful analysis of Longevity Health’s strategic strategy, including its financial disclosures and merger ambitions, the Nasdaq panel rendered its decision. Shortly after submitting the S-4 registration statement for the transaction on May 8, 2025, XAGE executed a 1-for-30 reverse stock split on May 12, 2025, in order to comply with Nasdaq regulations. By giving the business a significant exemption, the Panel’s ruling gives it more time to complete the merger and prove that it fully complies with listing requirements.

Merger Momentum and Product Launch Plans

With regulatory clearance in hand, Longevity Health is now intensifying efforts to complete the merger with 20/20 BioLabs. Post-merger, the combined company plans to introduce a medicated cleanser targeted for use in physicians’ offices and MedSpas. This product will be cross-promoted to 20/20 BioLabs’ customer network, which primarily includes firefighters.

Conversely, 20/20 BioLabs is preparing to release a diagnostic lab test designed to detect inflammatory biomarkers associated with premature aging and skin disorders. This new offering will be marketed to Longevity Health’s established network of healthcare providers and MedSpa professionals.

New Partnerships Expand Market Reach

In parallel with the merger, 20/20 BioLabs has embarked on a retail initiative with Giant Food, piloting its OneTest multi-cancer screening product at nine stores in Maryland and Virginia. The supermarket chain is also thinking about expanding the partnership to include biomarker testing for items that cause inflammation, which might generate more income for the combined company.

These accomplishments highlight a pivotal period of change for 20/20 BioLabs and Longevity Health (XAGE), with strategic synergies poised to redefine their combined market presence.